Posts about:
We often hear the word “depression” used casually — but for those living with major depressive disorder (MDD), it’s far more than a passing mood. Depression can affect nearly every part of a person’s life, from sleep and energy to relationships and decision-making.
Shaping the Future of Mental Health Care
At Segal Trials, we’ve been dedicated to advancing mental health research since 1998. With over two decades of experience and a passionate team of experts, we’re proud to support new research that could change lives.
If you or someone you know is struggling with depression and looking for new options, a research study may be a step worth exploring.
👉 Explore Current Studies
Depression affects more than 264 million people worldwide. While traditional treatments like SSRIs and psychotherapy have provided relief for many, a significant portion of individuals continue to experience persistent symptoms. Recent advancements in clinical research up to 2024 have introduced innovative therapies, offering renewed hope for those with treatment-resistant depression.
The holiday season is often depicted as a time of joy and celebration, yet for many, it can be a period marked by heightened emotional challenges. Depression during Christmas and sadness during the holidays are common feelings. These emotions may come from various sources, such as family dynamics, increased stress, and societal pressures.
Postpartum depression (PPD) continues to be a significant challenge affecting many new mothers, altering the joyous occasion of childbirth into a time of struggle and emotional turmoil. With advances in medical research, new treatment avenues are opening up, offering hope where traditional methods might fall short. One such promising field is the use of psychedelics in treating mood disorders like PPD.
The resurgence of interest in psychedelics, once sidelined by regulatory crackdowns and societal skepticism, marks a pivotal turn in the quest for effective mental health treatments. Psychedelic drugs, encompassing substances like psilocybin (found in magic mushrooms), LSD, MDMA (ecstasy), and ayahuasca, have moved from the fringes of scientific inquiry to the forefront of innovative psychiatric research. This article delves into how psychedelics are revolutionizing the treatment of mental illnesses such as anxiety, depression, addiction, and PTSD, the limitations of current pharmaceutical options, and the promising horizon of psychedelic-assisted therapy, underscored by rigorous clinical research aiming for FDA approval.
Exploring treatment-resistant depression (TRD), this article highlights new research and strategies offering hope through understanding risk factors, rethinking depression's causes, and innovative management methods.
The contributions made to our community from caregivers is monumental, and we want to provide resources, information, and the latest news to help support them. Please share this blog with other caregivers, family and friends and be sure to leave us a comment below.
Exploring how the lingering effects of COVID-19 in 2023 further influence depression rates and mental health challenges.
Postpartum depression (PPD) is a complex mood disorder that affects many new mothers in the weeks and months following childbirth. It’s essential to understand that PPD is more than just "baby blues," a term used to describe the mild, short-term sadness many women feel after giving birth. The symptoms of PPD can range from persistent feelings of sadness, hopelessness, and worthlessness to overwhelming fatigue, severe anxiety, and even thoughts of harming oneself or the baby. Some of the contributing factors include hormonal changes after childbirth, a history of depression or anxiety, childbirth-related trauma, and various stressors associated with new motherhood.